Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.42 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.42 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL30669763 | 1.00 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| Water SCHEMBL2441113 | 1.00 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| Chloramine-T Anhydrous SCHEMBL19335 | 0.98 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL8908023 | 0.98 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL31448661 | 0.98 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL2372301 | 0.98 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL7687453 | 0.96 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| Hydrochloric Acid SCHEMBL7829340 | 0.96 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| Ammonia Solution, Strong SCHEMBL3915653 | 0.96 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| Phosphine SCHEMBL7592008 | 0.96 | GAA (0.50) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582728-B2 | Theranostic agents for PSMA positive cancers | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-24 | — | — | US | claimed |
| US-12506011-B2 | Methods for wet atomic layer etching of transition metal oxide dielectric materials | TOKYO ELECTRON LIMITED (JP) | 2025-12-23 | — | — | US | claimed |
| US-20250308929-A1 | METHODS FOR WET ATOMIC LAYER ETCHING OF TUNGSTEN USING HALOGENATION | TOKYO ELECTRON LIMITED (JP) | 2025-10-02 | — | — | US | claimed |
| WO-2025128187-A1 | METHODS FOR WET ATOMIC LAYER ETCHING OF TRANSITION METAL OXIDE DIELECTRIC MATERIALS | TOKYO ELECTRON LIMITED (JP) | 2025-06-19 | — | — | WO | claimed |
| US-20250201572-A1 | METHODS FOR WET ATOMIC LAYER ETCHING OF TRANSITION METAL OXIDE DIELECTRIC MATERIALS | TOKYO ELECTRON LIMITED (JP) | 2025-06-19 | — | — | US | claimed |
| EP-4281779-A1 | STAINED BIOLOGICAL SPECIMENS INCLUDING ONE OR MORE BIOMARKERS LABELED WITH ONE OR MORE DETECTABLE MOIETIES | Ventana Medical Systems, Inc. (US) | 2023-11-29 | — | — | EP | claimed |
| CN-116496359-A | Tumor targeting diagnosis and treatment method based on HER2 affibody with tyrosine | 元本(珠海横琴)生物科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230200387-A9 | HALO ACTIVE AROMATIC SULFONAMIDE ANTIMICROBIAL COMPOSITIONS | Rem Brands, Inc. | 2023-06-29 | — | — | US | claimed |
| EP-4195927-A1 | HALO ACTIVE AROMATIC SULFONAMIDE ANTIMICROBIAL AND ODOR CONTROL COATINGS | Rem Brands, Inc. (US) | 2023-06-21 | — | — | EP | claimed |
| US-20230022833-A1 | MASONRY BASED MATERIALS WITH ANTI ODOR AND MICROBIAL CHARACTERISTICS | Rem Brands, Inc. | 2023-01-26 | — | — | US | claimed |
| WO-2022156920-A1 | STAINED BIOLOGICAL SPECIMENS INCLUDING ONE OR MORE BIOMARKERS LABELED WITH ONE OR MORE DETECTABLE MOIETIES | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| EP-4021455-A1 | NOVEL THERANOSTIC AGENTS FOR PSMA POSITIVE CANCERS | Memorial Sloan Kettering Cancer Center (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114181155-A | Iodine-enzalutamide and preparation method and application thereof | 上海朝晖药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-104524593-A | Method for releasing medicines by virtue of ester bond rupture | UNIV CHANGZHOU | 2015-04-22 | — | — | CN | claimed |
| CN-104529993-A | Preparation method of medicine micro-molecules containing unsaturated carbonyl | UNIV CHANGZHOU | 2015-04-22 | — | — | CN | claimed |
| CN-101830765-A | Method for synthesizing o-halohydrin | UNIV FUDAN | 2010-09-15 | — | — | CN | claimed |
| EP-1317460-A4 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2005-04-20 | — | — | EP | claimed |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-02-26 | — | — | US | claimed |
| EP-1317460-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-06-11 | — | — | EP | claimed |
| WO-2002018391-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230200387-A9 | HALO ACTIVE AROMATIC SULFONAMIDE ANTIMICROBIAL COMPOSITIONS | TYR, ARG1, HAX1 | MMP1 1370/4885MMP8 346/4885MMP13 2558/4885 |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | OXER1, OXA1L, AOX1 | MMP1 4080/4885MMP8 3199/4885MMP13 3703/4885 |
| US-12582728-B2 | Theranostic agents for PSMA positive cancers | PSMA1, PSMA2, KLK3 | MMP1 1702/4885MMP8 3727/4885MMP13 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.